Bayer (BAYA) Stock Price & Analysis
BAYA Stock Chart & Stats
- Day’s Range
- EUR 12.30 - EUR 12.70
- 52-Week Range
- EUR 6.35 - EUR 13.70
- Previous Close
- EUR 11.70
- Volume
- 0
- Average Volume (3M)
- 212
- Market Cap
- EUR 49.69B
- Enterprise Value
- EUR 93.55B
- Total Cash (Recent Filing)
- EUR 4.29B
- Total Debt (Recent Filing)
- EUR 38.42B
- Price to Earnings (P/E)
- ―
- Beta
- 1.13
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.21%
Bulls Say, Bears Say
Bulls Say
Crop Science Growth And Margins
Crop Science is showing both revenue growth and strong profitability, suggesting improved mix and operating execution rather than growth purchased solely through volume. A 31% EBITDA margin provides a durable earnings base and supports reinvestment across Bayer’s agricultural portfolio.
Pharma Growth Assets
Rapid growth from Nubeqa and Kerendia is helping offset pressure elsewhere in Pharma and demonstrates that Bayer has commercially relevant growth assets within its portfolio. Their momentum can improve mix and sustain pharmaceutical earnings as older products mature.
Balance-sheet And Litigation Actions
The Apollo equity investment and successful bond placement strengthen Bayer’s financing position while supporting an expected reduction in net financial debt. Combined with the favorable litigation ruling, these actions may improve medium-term financial flexibility and reduce pressure from legal liabilities.
Bears Say
Persistent Net Losses
Persistent net losses show that Bayer’s strong gross margins are not yet translating into sustainable bottom-line profitability. Continued earnings weakness can constrain internal investment, reduce resilience during operating setbacks, and make the company more dependent on portfolio and cost improvements.
Leverage And Weaker Cash Conversion
Elevated leverage reduces Bayer’s flexibility when earnings are under pressure, while deteriorating free cash flow weakens its ability to reduce debt organically. Together, these conditions increase the importance of successful financing actions and sustained operating cash generation over the coming quarters.
Eylea Competitive Pressure
A 27% decline in Eylea sales indicates a durable competitive challenge rather than a temporary reporting fluctuation, as biosimilars can continue affecting volumes and pricing. Ongoing erosion in this franchise places greater pressure on newer products to replace established pharmaceutical revenue.
Bayer News
Bayer’s Vericiguat Heart Failure Study in India: What the Real‑World Data Could Mean for BAYRY
Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer’s latest update on NCT06632483 covers a completed observational study in India that reviews real‑world use of vericiguat in
BAYA FAQ
What was Bayer’s price range in the past 12 months?
What is Bayer’s market cap?
When is Bayer’s upcoming earnings report date?
How were Bayer’s earnings last quarter?
Is Bayer overvalued?
Does Bayer pay dividends?
What is Bayer’s EPS estimate?
How many shares outstanding does Bayer have?
What happened to Bayer’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bayer?
What is the TipRanks Smart Score and how is it calculated?
Bayer Stock Smart Score
Company Description
Bayer
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Bill Anderson
- Employees
- 88,078
- Website
- www.bayer.com
- Address
- Kaiser-Wilhelm-Allee 1, Leverkusen, NW, 51368, DE
Bayer (BAYA) Earnings & Revenues
BAYA Company Deck
BAYA Earnings Call
Earnings Call SentimentPositive
The call presented multiple clear operational and strategic positives — steady group sales (+3%), EBITDA improvement (+7%), Crop Science margin expansion to 31%, strong growth in several Pharma assets (Nubeqa and Kerendia +66%), successful capital transactions (EUR 3bn Apollo investment and USD 5bn bond issuance) and a favorable U.S. Supreme Court ruling that materially strengthens litigation containment. Offsetting these strengths are meaningful near-term financial drains: negative free cash flow (‑EUR 2.7bn) driven by EUR 2.5bn in litigation payouts, elevated net debt in the near term (EUR 33.6bn), a 17% drop in Q2 core EPS due to normalization, Eylea sales down 27%, and continued legal and external-market risks. On balance, the highlights materially outweigh the lowlights given improving profitability, strategic progress, and decisive financing actions that reduce medium-term balance-sheet risk.
View all DE:BAYA earnings summariesBAYA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 4 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
